ASSET PURCHASE AGREEMENT by and between GENAISSANCE PHARMACEUTICALS, INC. and DNA SCIENCES, INC. Dated as of March 28, 2003Asset Purchase Agreement • May 15th, 2003 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research • Delaware
ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of March 28, 2003, by and between Genaissance Pharmaceuticals, Inc., a Delaware corporation (including its assignees, the “Purchaser”), and DNA Sciences, Inc., a Delaware corporation (the “Seller”, and together with the Purchaser, each, a “Party” and, collectively, the “Parties”).
AMENDMENT TO MASTER EQUIPMENT LEASE AGREEMENT NO. 7667 DATED JUNE 10,1999Master Equipment Lease Agreement • May 15th, 2003 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research
AMENDMENT (this “Amendment”) to Master Equipment Lease Agreement No. 7667 between General Electric Capital Corporation (successor-in-interest to Oxford Venture Finance, LLC), as lessor (the “Lessor”) and Genaissance Pharmaceuticals, Inc., as lessee (the “Lessee”) dated June 10, 1999 (together with all lease schedules, riders, and attendant documents, the “Lease”). This Amendment is entered into pursuant to and incorporates all of the terms and provisions of the Lease. By its execution and delivery of this Amendment, Lessee hereby reaffirms all of the representations, warranties and covenants contained in the Lease as of the date hereof.
DNA SCIENCES, INC. AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • May 15th, 2003 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research • Delaware
This Amendment No. 1 to Asset Purchase Agreement (“Amendment”) is made as of May 5, 2003, by and between Genaissance Pharmaceuticals, Inc., a Delaware corporation (the “Purchaser”) and DNA Sciences, Inc., a Delaware corporation (the “Seller” and, together with the Purchaser, each, a “Party” and, collectively, the “Parties”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Asset Purchase Agreement (as defined below).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. GENOTYPING SERVICES AGREEMENTGenotyping Services Agreement • May 15th, 2003 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research • Michigan
This GENOTYPING SERVICES AGREEMENT (the “Agreement”) is made as of the 11 day of March 2003 (the “Effective Date”), by and between Genaissance Pharmaceuticals, Inc., with its principal place of business at Five Science Park, New Haven, CT 06511 (“Genaissance”), and Wayne State University, with offices at 5700 Cass Avenue, Suite 4200, A.A. B., Detroit, MI 48202 (“WSU”).
January 27, 2003 Dr. Krishnan Nandabalan Vice President, Alliances Genaissance Pharmaceuticals, Inc.Genaissance Pharmaceuticals Inc • May 15th, 2003 • Services-commercial physical & biological research
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. TECHNOLOGY AND DATABASE LICENSE AGREEMENTTechnology and Database License Agreement • May 15th, 2003 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research • Massachusetts
This Technology and Database License Agreement (the “Agreement”) dated the 7th day of January 2003 (the “Effective Date”) is by and between Millennium Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 75 Sidney Street, Cambridge, Massachusetts 02139 (“Millennium”) and Genaissance Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at Five Science Park, New Haven, Connecticut 06511 (“Genaissance”).
